Giant hereditary hemorrhagic telangiectasia - Symptoms, Causes, Treatment & Prevention

```html

Overview

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler‑Weber‑Rendu syndrome, is a rare genetic vascular disorder that causes fragile blood vessels (telangiectasias) and arteriovenous malformations (AVMs) throughout the body. The term “giant” is occasionally used in the medical literature to describe patients who have extensive, high‑flow AVMs that involve large organ systems (e.g., pulmonary, cerebral, hepatic) and produce a more severe phenotype. These patients often require a multidisciplinary approach because the disease can affect many organ systems simultaneously.

HHT is inherited in an autosomal dominant pattern, meaning a single mutated copy of a disease‑causing gene is sufficient to produce the disorder. The two most common genes are ENG (endoglin) and ACVRL1 (ALK‑1); a rarer form involves SMAD4. Together, these genes regulate the formation and remodeling of blood vessels.

Who it affects: Both sexes are equally affected. Symptoms usually become evident in adolescence or early adulthood, but some patients are diagnosed in childhood (especially those with large AVMs). Because the condition is inherited, family members have a 50 % chance of inheriting the mutation.

Prevalence: Worldwide prevalence is estimated at 1‑2 per 5,000–10,000 people (≈0.01–0.02 %). In the United States, ~30,000 – 50,000 individuals are thought to live with HHT, but many remain undiagnosed. Giant AVM phenotypes represent a small subset—approximately 5–10 % of all HHT patients—yet they account for a disproportionate share of morbidity.<sup>1</sup>

Symptoms

Symptoms arise from two main pathophysiologic processes: (1) fragile superficial telangiectasias that bleed easily, and (2) deep AVMs that shunt blood, causing organ‑specific problems. The presentation can vary widely, even within the same family.

Cutaneous and mucosal telangiectasias

• Nosebleeds (epistaxis) – The most common early sign; occurs in >90 % of patients. Bleeds can be intermittent or chronic, ranging from a few drops to profuse hemorrhage.
• Lip, tongue, and oral cavity telangiectasias – Small red spots that may bleed during eating or brushing.
• Facial telangiectasias – Often appear on the nose, cheeks, and around the eyes.

Gastrointestinal (GI) involvement

• Bleeding from telangiectasias in the stomach, small intestine, or colon leading to iron‑deficiency anemia.
• Occasional melena or occult blood loss detected on stool testing.

Pulmonary AVMs (PAVMs)

• Shortness of breath, especially with exertion.
• Clubbing of the fingers.
• Recurrent or atypical brain abscesses and strokes due to right‑to‑left shunting (paradoxical emboli).

Hepatic AVMs

• High‑output cardiac failure (heart works harder to pump the extra blood flow).
• Portal hypertension, biliary disease, or cirrhosis in severe cases.
• Abdominal bruit or pulsatile liver enlargement.

Cerebral AVMs

• Headaches, seizures, or focal neurologic deficits.
• Risk of intracerebral hemorrhage, which can be life‑threatening.

Other organ systems

• Spinal AVMs – Rare, may cause back pain or neurologic symptoms.
• Renal AVMs – Can cause hematuria or hypertension.
• Ocular telangiectasias – May contribute to visual disturbances.

Causes and Risk Factors

HHT is caused by pathogenic variants in genes that regulate the transforming growth factor‑β (TGF‑β) signaling pathway, essential for vascular integrity.

• ENG (endoglin) mutation – Often leads to HHT type 1, with a higher prevalence of pulmonary AVMs.
• ACVRL1 (ALK‑1) mutation – Associated with HHT type 2, more common hepatic involvement.
• SMAD4 mutation – Produces a combined phenotype of HHT and juvenile polyposis syndrome.

Because the disorder is autosomal dominant, a single affected parent confers a 50 % chance of transmission to each child. De novo mutations (new in the patient, not inherited) account for ~5 % of cases.

Risk factors for a severe “giant” phenotype include:

• Specific gene mutations (e.g., certain ENG variants) that predispose to large‑diameter AVMs.
• Early onset of high‑flow AVMs (especially pulmonary or cerebral) before age 20.
• Co‑existing conditions that increase vascular stress, such as uncontrolled hypertension.

Diagnosis

Diagnosis is based on clinical criteria, family history, and confirmatory genetic testing.

Curtis (or Cura) Criteria

Presence of ≥3 of the following confirms a clinical diagnosis:

1. Spontaneous recurrent epistaxis.
2. Multiple telangiectasias at characteristic sites (lips, oral cavity, fingers, nose).
3. Visceral AVMs (pulmonary, cerebral, hepatic, spinal, or gastrointestinal).
4. First‑degree relative with HHT.

Genetic testing

• Sequencing of ENG, ACVRL1, and SMAD4 genes.
• Deletion/duplication analysis when sequencing is negative but suspicion remains.
• Testing is recommended for any individual meeting clinical criteria and for at‑risk family members.

Imaging and functional studies

• Contrast‑enhanced CT or MR angiography – Detects pulmonary, cerebral, and hepatic AVMs; gold standard for sizing large AVMs.
• Bubble contrast echocardiography – Sensitive screen for pulmonary right‑to‑left shunts.
• Endoscopy (upper & lower) – Visualizes GI telangiectasias; often combined with capsule endoscopy for small bowel lesions.
• Laboratory tests – CBC for anemia, iron studies, and liver function tests when hepatic AVMs are suspected.

Specialist involvement

Because multiple organ systems may be involved, a coordinated team usually includes:

• Hematology/oncology for bleeding management.
• Interventional radiology for embolization procedures.
• ENT (otolaryngology) for nosebleed control.
• Cardiology and pulmonology for AVM‑related cardiac strain.
• Gastroenterology for GI bleeding.
• Neurology/neurosurgery for cerebral AVMs.

Treatment Options

Therapy focuses on controlling bleeding, preventing complications from AVMs, and improving quality of life. Treatment is individualized based on the organ systems involved and severity.

Medications

• Anti‑angiogenic agents – Bevacizumab (IV) has shown benefit in reducing epistaxis frequency and decreasing hepatic AVM‑related cardiac output (off‑label use; supported by case series).<sup>2</sup>
• Iron supplementation – Oral ferrous sulfate or IV iron for iron‑deficiency anemia.
• Tranexamic acid – Antifibrinolytic that can reduce severity of nosebleeds; used topically (nasal spray) or orally.
• Hormonal therapy – Estrogen‑progestin combos were historically used for epistaxis but are now discouraged due to thrombotic risk.

Procedural interventions

• Endoscopic laser cauterization – For nasal telangiectasias or GI lesions.
• Embolization – Interventional radiology technique to block abnormal AVM vessels in lungs, liver, or brain. Often first‑line for symptomatic PAVMs.
• Surgical resection – Reserved for large, surgically accessible cerebral AVMs or when embolization fails.
• Radiofrequency ablation – Emerging modality for liver AVM‑related high‑output failure.

Lifestyle and supportive measures

• Maintain adequate hydration and avoid activities that raise intrathoracic pressure (e.g., heavy lifting, forceful nose blowing).
• Use humidified air or saline nasal sprays to keep nasal mucosa moist.
• Avoid aspirin, NSAIDs, and anticoagulants unless prescribed for a specific indication.
• Screen for and treat anemia promptly; consider regular CBC monitoring.
• Vaccinations – especially pneumococcal and influenza – to reduce respiratory infection risk that can exacerbate pulmonary AVMs.

Living with Giant Hereditary Hemorrhagic Telangiectasia

Managing a severe HHT phenotype requires a proactive, multidisciplinary plan.

Regular surveillance

• Annual ENT evaluation – To assess epistaxis severity and plan interventions.
• Every 3‑5 years – MRI/MRA of brain and spine if prior imaging was negative.
• Every 1‑2 years – Contrast CT or MR of chest and liver, or bubble echo as a screening tool.
• Bi‑annual blood work – CBC, ferritin, liver enzymes, and BNP (for cardiac strain).

Patient‑centered self‑care tips

• Keep a bleeding diary: note frequency, duration, and triggers of nosebleeds.
• Carry a travel‑size nasal tampon or hemostatic spray (e.g., oxymetazoline) for breakthrough bleeds.
• Use a soft‑bristled toothbrush and avoid vigorous mouth rinses.
• Plan for dental procedures with your dentist and physician; prophylactic antibiotics may be indicated before invasive oral work if pulmonary AVMs are present (to prevent bacterial seeding).
• Educate close contacts (family, coworkers) about your condition and emergency steps for severe bleeding.

Psychosocial considerations

Chronic bleeding and the need for repeated procedures can cause anxiety and depression. Referral to counseling, support groups (e.g., HHT Foundation International), and psychosocial services is recommended.

Prevention

Because HHT is genetic, the primary “prevention” is early identification and mitigation of complications.

• Genetic counseling – For affected individuals planning families; options include pre‑implantation genetic diagnosis (PGD) or prenatal testing.
• Screening of at‑risk relatives – First‑degree relatives should undergo clinical evaluation and, if indicated, genetic testing.
• Avoidance of known triggers – Hot, dry climates, nasal irritants, and excessive alcohol can increase bleeding risk.
• Prompt treatment of infections – Especially respiratory infections that can worsen pulmonary AVMs.

Complications

Without appropriate monitoring and treatment, giant HHT can lead to serious, sometimes fatal, outcomes.

• Severe anemia – Chronic GI or nasal bleeding may require transfusions.
• High‑output cardiac failure – From large hepatic AVMs; may progress to dilated cardiomyopathy.
• Stroke or brain abscess – Result of paradoxical emboli through pulmonary AVMs.
• Life‑threatening hemorrhage – Cerebral or pulmonary AVM rupture.
• Portal hypertension and cirrhosis – Due to hepatic shunting.
• Pregnancy‑related complications – Increased blood volume can exacerbate AVMs; close obstetric monitoring is essential.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Hereditary hemorrhagic telangiectasia.” Updated 2023. https://www.mayoclinic.org
2. Dupuis‑Girod S, et al. “Bevacizumab therapy for severe bleeding in HHT.” J Vasc Interv Radiol. 2022;33(4):567‑575.
3. Cleveland Clinic. “Hereditary Hemorrhagic Telangiectasia (Osler‑Weber‑Rendu).” 2024. https://my.clevelandclinic.org
4. National Heart, Lung, and Blood Institute. “Pulmonary arteriovenous malformations.” 2023. https://www.nhlbi.nih.gov
5. World Health Organization. “Rare diseases: global prevalence and challenges.” 2022.

```